We also evaluated p16INK4a expression in all HR-HPV-positive samples by immunohistochemistry (IHC) to determine whether it is a surrogate marker for E7 expression in prostate cancer with HR-HPV infection. This evidence concerns the gene CDKN2A and prostate carcinoma.